103 related articles for article (PubMed ID: 3906779)
1. [Syntheses of [prolyl-U-14C]alacepril and its related compounds].
Kagemoto A; Nakao M; Negoro T; Sekine Y; Hashimoto M
Radioisotopes; 1985 Aug; 34(8):408-13. PubMed ID: 3906779
[TBL] [Abstract][Full Text] [Related]
2. Disposition and metabolism of the novel antihypertensive agent alacepril in rats.
Matsumoto K; Miyazaki H; Fujii T; Yoshida K; Amejima H; Hashimoto M
Arzneimittelforschung; 1986; 36(1):40-6. PubMed ID: 3513776
[TBL] [Abstract][Full Text] [Related]
3. Tissue levels, tissue angiotensin converting enzyme inhibition and antihypertensive effect of the novel antihypertensive agent alacepril in renal hypertensive rats.
Nambu K; Matsumoto K; Takeyama K; Hosoki K; Miyazaki H; Hashimoto M
Arzneimittelforschung; 1986; 36(1):47-51. PubMed ID: 3006710
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of protein conjugate of desacetyl-alacepril and its effect on angiotensin converting enzyme in renal hypertensive rats.
Matsumoto K; Nambu K; Fujii T; Takeyama K; Miyazaki H; Hashimoto M
Arzneimittelforschung; 1986; 36(1):52-4. PubMed ID: 3006711
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive activity of alacepril in spontaneously hypertensive rats and deoxycorticosterone acetate-salt hypertensive rats and dogs.
Takeyama K; Minato H; Fukuya F; Kawahara S; Hosoki K; Kadokawa T
Arzneimittelforschung; 1985; 35(10):1507-12. PubMed ID: 3000390
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive mechanism of alacepril: effect on norepinephrine-induced vasoconstrictive response in vitro and in vivo.
Takeyama K; Minato H; Ikeno A; Hosoki K; Kadokawa T
Arzneimittelforschung; 1986; 36(1):74-7. PubMed ID: 3513780
[TBL] [Abstract][Full Text] [Related]
7. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 1st communication: Effects on cardiovascular, visceral and renal functions and on blood.
Matsuno Y; Taira N; Fujitani B; Ito T; Kadokawa T
Arzneimittelforschung; 1986; 36(1):55-62. PubMed ID: 3513777
[TBL] [Abstract][Full Text] [Related]
8. Antihypertensive activity of alacepril, an orally active angiotensin converting enzyme inhibitor, in renal hypertensive rats and dogs.
Takeyama K; Minato H; Fukuya F; Kawahara S; Hosoki K; Kadokawa T
Arzneimittelforschung; 1985; 35(10):1502-7. PubMed ID: 3000389
[TBL] [Abstract][Full Text] [Related]
9. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 2nd communication: Effects on central nervous and sensory systems and on the other functions.
Matsuno Y; Hori H; Oka M; Nakamura H; Ito T; Kadokawa T
Arzneimittelforschung; 1986; 36(1):62-8. PubMed ID: 3513778
[TBL] [Abstract][Full Text] [Related]
10. Effect of the novel orally active angiotensin converting enzyme inhibitor alacepril on cardiovascular system in experimental animals.
Takeyama K; Minato H; Nakatsuji K; Suzuki H; Nose I; Oka M; Hosoki K; Hatano N; Kadokawa T
Arzneimittelforschung; 1986; 36(1):69-73. PubMed ID: 3513779
[TBL] [Abstract][Full Text] [Related]
11. Effect of alacepril on renin-angiotensin-aldosterone system and kallikrein-kinin-prostaglandin system in experimental animals.
Hosoki K; Takeyama K; Minato H; Fukuya F; Kawahara S; Kadokawa T
Arzneimittelforschung; 1986; 36(1):77-83. PubMed ID: 3006712
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive mechanism of alacepril. Effects of its metabolites on the peripheral sympathetic nervous system.
Minato H; Hosoki K; Hayashi K; Sawayama T; Kadokawa T; Hashimoto M
Arzneimittelforschung; 1989 Mar; 39(3):319-24. PubMed ID: 2547387
[TBL] [Abstract][Full Text] [Related]
13. Acute effects of the new oral angiotensin converting enzyme inhibitor 1-(D-3-acetylthio-2-methylpropanoyl)-L-prolyl-L-phenylalanine (Alacepril) in essential hypertension.
Mizuno K; Hashimoto S; Kunii N; Tani M; Niimura S; Yabe R; Watari H; Fukuchi S
Res Commun Chem Pathol Pharmacol; 1985 Aug; 49(2):175-87. PubMed ID: 2997886
[TBL] [Abstract][Full Text] [Related]
14. Effect of antihypertensive treatment with alacepril on insulin resistance in diabetic spontaneously hypertensive rats.
Sato T; Nara Y; Kato Y; Yamori Y
Metabolism; 1996 Apr; 45(4):457-62. PubMed ID: 8609831
[TBL] [Abstract][Full Text] [Related]
15. Long-term plasma levels and dose modulation of alacepril in patients with chronic renal failure.
Nonoguchi H; Kiyama S; Kitamura K; Naruse M; Tomita M; Tazoe N; Tajiri M; Nakayama Y; Kohda Y; Inoue T; Tomita K
Hypertens Res; 2008 Jan; 31(1):29-36. PubMed ID: 18360015
[TBL] [Abstract][Full Text] [Related]
16. Determination of captopril and its mixed disulphides in plasma and urine by high-performance liquid chromatography.
Hayashi K; Miyamoto M; Sekine Y
J Chromatogr; 1985 Feb; 338(1):161-9. PubMed ID: 3894398
[TBL] [Abstract][Full Text] [Related]
17. Sialic acid 9-O-acetylesterase catalyzes the hydrolyzing reaction from alacepril to deacetylalacepril.
Usui S; Kubota M; Iguchi K; Kiho T; Sugiyama T; Katagiri Y; Hirano K
Pharm Res; 2003 Aug; 20(8):1309-16. PubMed ID: 12948030
[TBL] [Abstract][Full Text] [Related]
18. Free radical scavenging properties of alacepril metabolites and lisinopril.
Noda Y; Mori A; Packer L
Res Commun Mol Pathol Pharmacol; 1997 May; 96(2):125-36. PubMed ID: 9226747
[TBL] [Abstract][Full Text] [Related]
19. Effects of alacepril and amlodipine on the renal injury induced by a high-cholesterol diet in rats.
Atarashi K; Takagi M; Minami M; Ishiyama A
J Hypertens; 1999 Dec; 17(12 Pt 2):1983-6. PubMed ID: 10703899
[TBL] [Abstract][Full Text] [Related]
20. Effects of the angiotensin converting enzyme inhibitors captopril, rentiapril, and alacepril in patients with essential and renovascular hypertension.
Ideishi M; Sasaguri M; Ikeda M; Arakawa K
Clin Ther; 1989; 11(4):441-51. PubMed ID: 2550133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
